All News

Focus group participants were receptive to using eHealth tools, but noted several barriers such as cost and availability.

Participants were asked to rate their level of concern on 26 health topics.

In case you missed it, this week we had news about digital therapeutics for depression, bracing for fall allergies, at-home tests for sexually transmitted infections, and more.

Check out this recap of articles published on our sister sites during the past week.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

First To Know Syphilis Tests are expected to be available at major national retailers and online in late 2024.

Tom DePietro, PharmD, owner of DePietro’s Pharmacy in Dunmore, Pennsylvania, discussed his experience as an independent pharmacy owner working under the thumb of pharmacy benefit managers.

Check out important updates from the FDA for the week of August 12.

The partnership’s revolutionary new product is set to premiere at the National Association of Chain Drug Stores’ Total Store Expo in Boston, Massachusetts, kicking off on August 17, 2024.

A CDC report called for “increased efforts” to ensure parents can obtain all recommended vaccines for their eligible children and realize the full potential of the VFC program.

New prices will go into effect on January 1, 2026, for individuals covered by Medicare Part D prescription drugs.

Izokibep from Affibody is a small therapeutic protein designed to inhibit IL-17A.

Medtronic also announced it has entered a global partnership with Abbott in an effort to expand CGM device options for patients living with diabetes.

Tom DePietro, PharmD, owner of DePietro’s Pharmacy in Dunmore, Pennsylvania, talked about current movement toward PBM reform and his hopes for the future of pharmacy.

TAK-003 could be a powerful combatant against the increasing global threat of dengue virus.

Experts analyzed data from the National Center for Health Statistics on the leading causes of death in the US from the last 5 years.

Rejoyn, developed by Otsuka Pharmaceutical and Click Therapeutics, is only accessible with a prescription from a health care provider.

Two phase 3 trials evaluating nemolizumab found that 41% of patients treated with the therapy achieved at least a 4-point reduction in itch intensity at week 16.

Tom DePietro, PharmD, owner of DePietro’s Pharmacy in Dunmore, Pennsylvania, shared his thoughts on how patients are treated within the drug supply chain.

The FDA approved imetelstat (Rytelo) in June 2024.

Call Developed as Part of National Initiative with Stakeholder Input.

Ascendis Pharma said it is currently completing manufacturing of commercial product, which it anticipates will be available in the US in the first quarter of 2025.

Tom DePietro, PharmD, owner of DePietro’s Pharmacy in Dunmore, Pennsylvania, discussed the current state of independent pharmacy and the role pharmacy benefit managers play within the supply chain.

Our congressional representatives have plenty of interaction with PBM lobbyists. It’s time they hear from patients as well.

In case you missed it, this week we had news about opioid prescribing for patients with chronic pain, a possible link between cannabis and cancer, preparing for the upcoming flu season, and more.

Check out this recap of articles published on our sister sites during the past week.

Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.

The agency said it could not approve the new drug application based on the submitted data and requested an additional Phase 3 trial to “further study the safety and efficacy” of the therapy.